Clinical trials: AMD
Geographic Atrophy, Age-Related Macular Degeneration
Pharmacokinetic and Pharmacodynamic Study of Emixustat in Subjects With Geographic Atrophy Associated With Dry Age-Related Macular Degeneration
The purpose of this study is to characterize emixustat hydrochloride pharmacokinetic and pharmacodynamic parameters in subjects with geographic atrophy associated with dry age-related macular degeneration.
- Trial name
- NCT02130531
- Testing
- Emixustat HCl Tablet
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Kubota Vision Inc.
Wet Age-related Macular Degeneration (wAMD)
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
This Phase II study is designed to evaluate the efficacy and safety of AL-001 ophthalmic injection in patients with wet age-related macular degeneration.
- Trial name
- NCT06839339
- Testing
- AL-001, Aflibercept
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
Stargardt Disease-1
Study of STG-001 in Subjects With Stargardt Disease
This is an open-label, multicenter study in subjects with Stargardt disease, comparing 2 doses of STG-001 with regard to safety, pharmacokinetics and pharmacodynamics.
- Trial name
- NCT04489511
- Testing
- STG-001
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Stargazer Pharmaceuticals, Inc.
Macular Edema, Diabetic Macular Edema
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
This was an open-label, multi-center, FIH study with a single ascending dose (SAD) design that assessed the safety, tolerability and pharmacokinetics (PK) of a single IVT dose of MHU650 in up to 24 participants with macular edema.
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Trial name
- NCT04635800
- Testing
- MHU650
- Where
- 6 sites in United States, Puerto Rico
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Glycogen Storage Disease Type II
A Prospective Study to Observe & Describe Clinical Outcomes of Alglucosidase Alfa Treatment in Patients ≤6 Months of Age With Infantile-onset Pompe Disease (IOPD)
Primary Objective: To describe the effect of routine practice with alglucosidase alfa in patients with IOPD ≤6 months of age, on invasive ventilation-free survival after 52 weeks of treatment.
- Trial name
- NCT04848779
- Testing
- Alglucosidase alfa GZ419829
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 16 people
- Sponsor
- Sanofi
Neovascular Age-related Macular Degeneration
A Randomized, Double-masked, Multicenter, Controlled Study of Intravitreal KH902 in Patients With Neovascular AMD
This study is designed to access the safety and efficacy of multiple injections of KH902 at variable dosing regimens in patients with CNV due to neovascular AMD.
- Trial name
- AURORA (NCT01157715)
- Testing
- intravitreal injection of KH902
- Where
- 9 sites in China
- Volunteers
- 122 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Age-Related Macular Degeneration (AMD)
Phase 1 Study of Topical Ocular PAN-90806 for Neovascular AMD
The objective of this study is to assess the safety and tolerability of topical ocular PAN-90806 in patients with active, subfoveal choroidal neovascularization associated with neovascular Age-Related Macular Degeneration (AMD).
- Trial name
- NCT02022540
- Testing
- PAN-90806 Ophthalmic Solution, Lucentis
- Where
- 22 sites in United States
- Volunteers
- 50 people
- Sponsor
- PanOptica, Inc.
Neovascular AMD, Visual Impairment Due to DME, Visual Impairment Due to Macular Oedema Secondary to Branch or Central RVO, Visual Impairment Due to CNV
Observation of Treatment Patterns With Lucentis in Approved Indications
A multicentre, open-label, non-interventional study to observe treatment patterns in patients with wet age-related macular degeneration (wAMD), with visual impairment due to diabetic macular edema (DME), due to macular edema…
- Trial name
- OCEAN (NCT02194803)
- Where
- Germany
- Volunteers
- 5,778 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration
This multicenter, non-randomized, open-label, single- and multiple-ascending-dose study will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of RO6867461 in patients with wet age-related macular…
- Trial name
- NCT01941082
- Testing
- RO6867461
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Wet Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD)
- Trial name
- DAYBREAK (NCT06556368)
- Testing
- Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 675 people
- Sponsor
- Kodiak Sciences Inc
Macular Degeneration
A Study to Test How Well Different Doses of BI 754132 Are Tolerated in Patients With an Advanced Form of Age-related Macular Degeneration Called Geographic Atrophy
This is a study in adults with geographic atrophy, an advanced form of age-related macular degeneration. The purpose of this study is to find out how well different doses of BI 754132 are tolerated.
- Trial name
- NCT04002310
- Testing
- BI 754132
- Where
- 13 sites in United States, United Kingdom
- Volunteers
- 18 people
- Sponsor
- Boehringer Ingelheim
Age-Related Macular Degeneration
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.
- Trial name
- NCT03668054
- Testing
- Bevacizumab (Lumiere®)
- Where
- 3 sites in Argentina
- Volunteers
- 22 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
Wet Macular Degeneration
Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy
The main objectives of this non-interventional cohort field study are to evaluate effectiveness of Eylea and to describe follow-up as well as treatment patterns in patients with wAMD (wet age-related macular degeneration) in…
- Trial name
- PERSEUS-IT (NCT02289924)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Italy
- Volunteers
- 912 people
- Sponsor
- Bayer
AMD, Wet AMD
INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD
The purpose of this study is to confirm the safety and establish the effectiveness of two doses from the IRay System for the treatment of wet AMD.
- Conditions
- AMD, Wet AMD, Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration
- Trial name
- INTREPID (NCT01016873)
- Testing
- IRay
- Where
- 21 sites in Austria, Czechia and 3 more
- Volunteers
- 230 people
- Sponsor
- Oraya Therapeutics, Inc.
Macular Degeneration
EYLEA [AMD-QOL(Age-Related Macular Degeneration-Quality of Life)] Post-marketing Surveillance in Japan
The objective of this survey is to evaluate effectiveness of EYLEA on Quality of Life (QOL). The QOL is evaluated by using Japanese version (v.1.4 - interviewer administered format) of National Eye Institute Visual Function…
- Trial name
- NCT01756261
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 757 people
- Sponsor
- Bayer
Retinal Vein Occlusion
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Eylea for Central Retinal Vein Occlusion (CRVO)
This is a prospective, non-interventional, multi center post-authorization safety study that includes patients with a diagnosis of CRVO.
- Trial name
- JPMS-CRVO (NCT02040220)
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- Japan
- Volunteers
- 385 people
- Sponsor
- Bayer
AMD
Evaluate the Improving Effects of Visucomplex Plus on Quality of Life in Patients With AMD
This is an observational study in which patients affected by dry or wet AMD will be enrolled, after signing the Informed Consent, according to eligibility criteria.
- Trial name
- NCT04177069
- Testing
- Visucomplex Plus
- Where
- 4 sites in Italy
- Volunteers
- 160 people
- Sponsor
- VISUfarma SpA
Geographic Atrophy, Age-Related Macular Degeneration
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Age-related macular degeneration (AMD) is the abnormal growth of new blood vessels in the light-sensitive tissue at the back of the eye called the retina. Geographic Atrophy (GA) is an advanced form of dry AMD.
- Trial name
- NCT07160179
- Testing
- ABBV-6628, SYFOVRE
- Where
- 5 sites in United States
- Volunteers
- 66 people
- Sponsor
- AbbVie
Age-Related Macular Degeneration (ARMD)
Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration
Ranibizumab is derived from a murine monoclonal anti- vascular endothelial growth factor (VEGF) antibody and can penetrate through the many retinal cell layers following intravitreal injection.
- Trial name
- NCT00288561
- Testing
- ranibizumab
- Where
- Switzerland
- Sponsor
- Novartis
Macular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
- Trial name
- PINNACLE (NCT06996080)
- Testing
- KSI-101
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Kodiak Sciences Inc